查詢結果分析
相關文獻
- The Effects of Sequentially Combined Hormone Replacement Therapy on Climacteric Symptoms and Lipid Profiles
- Lactation Promotes the Normalization of Plasma Lipids and Lipoproteins after Delivery in Taiwanese Women
- 薏仁對高血脂病患血脂質及血糖的影響
- 孩童及青少年血脂異常的治療
- 十二週體能訓練對婦女健康體能與血脂肪之影響
- 蛋黃卵磷脂對於高血脂傾向大白鼠血脂質及肝脂質之影響研究
- Correlations of Serum Lipids, Uric Acid, and Albumin among Mothers, Offspring, and Siblings in Taipei, Taiwan
- Relationship between Hemostatic Factors and Known Cardiovascular Disease Correlates in Two Suburban Populations in Taiwan
- 認識血脂異常
- 停經婦女補充女性荷爾蒙之利弊
頁籤選單縮合
| 題 名 | The Effects of Sequentially Combined Hormone Replacement Therapy on Climacteric Symptoms and Lipid Profiles=週期性雌激素合併黃體素荷爾蒙補充療法對脂質代謝之影響 |
|---|---|
| 作 者 | 陳怡仁; 楊再興; 王懷麟; 張昇平; 袁九重; | 書刊名 | 臺灣婦產科醫學會會刊雜誌 |
| 卷 期 | 42:4 2003.12[民92.12] |
| 頁 次 | 頁235-242 |
| 分類號 | 418.27 |
| 關鍵詞 | 停經症狀; 荷爾蒙補充療法; 血脂; Climacteric symptoms; Hormone replacement therapy; Lipid profiles; |
| 語 文 | 英文(English) |
| 中文摘要 | 目的:週期性雌激素合併黃體素荷爾蒙補充療法對台灣停經婦女,其停經症狀及血脂之影響。材料和方法:57位停經婦女(45~60歲),隨機分配至兩組,一組接受Sevina®每日一顆,另一組(PP組)接受Premarine 0.625mg 每天一顆(每月第l天至30天)合併Provera 5mg每天一顆(每天第l天至第12天),第一、三兩組服用數個月後,皆有減少停經之症狀。但在PP組膽固醇沒改變,而Sevina®有降低膽固醇之情形。LDL-C在兩組皆下降,HDL在兩組皆不變,三酸甘油脂在Sevina®組下降,而在PP組增加。結論:本試驗中,Sevina®可降低LDL和膽固醇,而且不增加三酸甘油脂,並有效改善停經症狀,因此Sevina®可用於停經症候群之治療。 |
| 英文摘要 | Objectives: To compare the climacteric symptoms, bleeding patterns, and lipid metabolism in Taiwanese postmenopausal women using 2 different cyclic sequential hormone replacement regimens, containing either 1 to 2 mg 17βestradiol plus 1 mg norethisterone acetate (Sevina®) or 0.625 mg conjugated estrogen plus 5 mg medroxyprogesterone acetate (Premarin®/Provera®; PP). Material(s) and Method(s): Fifty-seven generally healthy, female, postmenopausal patients from 45 to 60 years of age were randomized into groups receiving either 1 tablet Sevina® daily or I tablet of 0.625 mg Premarin® daily with 1 tablet of 5 mg Provera® daily for the first 12 days (days 1 to 12) (PP group) for 6 months. Climacteric symptoms and bleeding patterns were assessed at the baseline and at 1, 3, and 6 months. The effects on lipid variables, hormone profiles, and liver function tests were measured at the baseline and at 6 months. Result(s): Both drugs produced a statistically significant reduction in most climacteric symptoms during the 6 months of treatment (p < 0.05). After 6 months of treatment, total cholesterol showed no significant change in the PP group, whereas there was a significant decrease in the Sevina® group. Meanwhile, low-density lipoprotein cholesterol also revealed a significant reduction in both treatment groups, while high-density lipoprotein cholesterol remained unchanged in both groups. The triglyceride level decreased in the Sevina® group, but showed a significant increase in the PP group (p < 0.05). There was also a significant difference between the 2 groups in changes in triglycerides. Conclusions: This study demonstrates that Sevina® is effective in decreasing low-density lipoprotein cholesterol and the total cholesterol level, without increasing the level of triglycerides, and can effectively alleviate climacteric symptoms during treatment. Sevina® is a highly effective and acceptable sequential hormone replacement regimen for the treatment of climacteric symptoms and lipid effects in postmenopausal women. |
本系統中英文摘要資訊取自各篇刊載內容。